APA (7th ed.) Citation

Herold, S., Schmidt, C., Visco, C., Tilch, M., Ohler, A., Unterhalt, M., . . . Dreyling, M. (2025). The MCL elderly III trial protocol: An international, randomized, open-label phase II trial to investigate the combinations of venetoclax, ibrutinib and rituximab or bendamustine, ibrutinib and rituximab in patients with treatment naive mantle cell lymphoma not eligible for dose-intensive treatment. BMC Cancer, 25(1), 1. https://doi.org/10.1186/s12885-025-14803-8

Chicago Style (17th ed.) Citation

Herold, Stephanie, et al. "The MCL Elderly III Trial Protocol: An International, Randomized, Open-label Phase II Trial to Investigate the Combinations of Venetoclax, Ibrutinib and Rituximab or Bendamustine, Ibrutinib and Rituximab in Patients with Treatment Naive Mantle Cell Lymphoma Not Eligible for Dose-intensive Treatment." BMC Cancer 25, no. 1 (2025): 1. https://doi.org/10.1186/s12885-025-14803-8.

MLA (9th ed.) Citation

Herold, Stephanie, et al. "The MCL Elderly III Trial Protocol: An International, Randomized, Open-label Phase II Trial to Investigate the Combinations of Venetoclax, Ibrutinib and Rituximab or Bendamustine, Ibrutinib and Rituximab in Patients with Treatment Naive Mantle Cell Lymphoma Not Eligible for Dose-intensive Treatment." BMC Cancer, vol. 25, no. 1, 2025, p. 1, https://doi.org/10.1186/s12885-025-14803-8.